nirogacestat,lenalidomide,teclistamab,daratumumab,pomalidomide,bortezomib
takeda,springworks therapeutics,janssen,genmab,bms
['majestec-2', 'dara+', 'mmsm', 'majestec,(-majestec-1),(-majestec1),(-majestec 1),(-majestec-3),(-majestec3),(-majestec 3),(-majestec-i),(-majestec i),(-majesteci)', 'rafael ']
majestec-2 tec+dara+len n=32. 1-3 prior lot crs 815 but g1/2, infections in 9%. orr 93.5% cr 54.8% #ash2022rf #mmsm
Chief Innovation Officer - Mayo Clinic in Arizona. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement